(Q38230650)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Current evidence of temozolomide and bevacizumab in treatment of gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Danop Nanegrungsunk

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Nipon Chattipakorn

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Siriporn C Chattipakorn

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

18 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Neurological Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

167-183

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

2007 World Health Organization classification of tumours of the central nervous system

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Emerging insights into the molecular and cellular basis of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Current management of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

State-of-the-art treatment of high-grade brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Glioma extent of resection and its impact on patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Assumptions in the radiotherapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Multifocal glioblastoma multiforme: prognostic factors and patterns of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Radiation dose-volume effects in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide: mechanisms of action, repair and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Glioma-associated endothelial cells are chemoresistant to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Initial chemotherapy in gliomatosis cerebri.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Radiotherapy with and without temozolomide in elderly patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132814Y.0000000423

10.1179/1743132814Y.0000000423

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25033940%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference